69 related articles for article (PubMed ID: 21348776)
1. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Quan WD; Gagnon GA; Walker PR; Quan FM
Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
[TBL] [Abstract][Full Text] [Related]
2. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
3. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
[TBL] [Abstract][Full Text] [Related]
4. High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Apr; 24(2):181-3. PubMed ID: 19409039
[TBL] [Abstract][Full Text] [Related]
5. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
7. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
8. Activity of outpatient intravenous interleukin-2 and famotidine in metastatic clear cell kidney cancer.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2014 Mar; 29(2):58-61. PubMed ID: 24251758
[TBL] [Abstract][Full Text] [Related]
9. High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Walker PR; Picton M; Quan FM; King LA; Tyre C; Liles DK
Cancer Biother Radiopharm; 2008 Oct; 23(5):641-6. PubMed ID: 18999936
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
[TBL] [Abstract][Full Text] [Related]
12. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
13. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Quan W; Knupp C; Quan F; Walker P
Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
[TBL] [Abstract][Full Text] [Related]
14. Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Quan WD; Quan FM; Perez M; Johnson E
Cancer Biother Radiopharm; 2012 Sep; 27(7):442-5. PubMed ID: 22731929
[TBL] [Abstract][Full Text] [Related]
15. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
16. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
[TBL] [Abstract][Full Text] [Related]
17. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
20. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
Quan WD; Khan N; Ramirez M; Taylor WC; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Apr; 20(2):151-4. PubMed ID: 15869448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]